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Whether tumours are epithelial or non-epithelial in origin, it is generally accepted that once they reach a certain size all solid tumours
are dependent upon a vascular supply to provide nutrients. Accordingly, there is great interest in how the extracellular environment
enhances or inhibits vascular growth. In this minireview, we will examine key extracellular components, their changes with ageing, and
discuss how these alterations may influence the subsequent development of tumour vasculature in the aged host. Because of the tight
correlation between advanced age and development of prostate cancer, we will use prostate cancer as the model throughout this
review.
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During an organism’s lifespan, almost every aspect of its
phenotype will undergo alterations, including the components of
the extracellular environment. It is increasingly evident that there
is a dynamic interaction between the molecules of the extracellular
space and the surrounding cells. The architecture of the
extracellular space is important for maintaining proper cellular
function; loss of tissue architecture is a defining characteristic of
epithelial cancers. A microenvironment that provides the correct
cues can serve as a powerful tumour suppressor and can even
revert cells containing preneoplastic as well as oncogenic
mutations back to a normal phenotype (Bissell and Radisky,
2001; Campisi, 2005; Nelson and Bissell, 2006). The processes of
living and ageing, however, continually alter the composition, and
thus the architecture, of the extracellular space.
Traditionally, interactions between tumour cells and various
growth factors have been the focus in cancer. However, there is
increasing interest in the roles of other proteins in the extracellular
environment on tumour progression. The term ‘microenviron-
ment’ now includes the extracellular matrix (collagens, laminins,
matricellular proteins) and soluble factors (hormones, cytokines,
growth factors, enzymes) that are released by resident and
circulating cells or secreted by other organs.
All non-circulating cells are physically linked to the extracellular
space via cell membrane receptors such as integrins and
syndecans. Signalling through these receptors influences changes
to the cell’s cytoskeleton network, which is connected to the
nuclear matrix and chromatin. Alterations in the cytoskeleton
modify gene expression, which in turn leads to changes in the
chemical and protein composition of the microenvironment
(Nelson and Bissell, 2006). In epithelial cancers, transformed
epithelial cells, reactive stroma, recruited blood vessels,
and infiltrating macrophages, lymphocytes, and leukocytes also
contribute to the microenvironment (Nelson and Bissell, 2006; Tan
and Coussens, 2007). In this review, we will use prostate cancer as
the model and focus on the potential roles of extracellular matrix
proteins and soluble factors during tumour angiogenesis in the
aged host (Figure 1).
EPITHELIAL CANCERS
Age-associated epithelial cancers, such as breast and prostate
cancer, contribute significantly to mortality in the elderly. One
possible mechanism by which the body defends itself against
epithelial cancers is to halt replication of damaged cells by
senescence, in which the cells are replicatively arrested but still
metabolically active. Since somatic mutations are believed to
accumulate throughout life, senescence is important in preventing
the formation of epithelial tumours in the young. Accumulation
of mutations alone, however, is not sufficient to cause cancer.
Currently, one view is that these ‘initiated’ cells require a
permissive microenvironment in which to progress (Campisi,
2005; Nelson and Bissell, 2006). The accruement of senescent cells
may provide such an environment due to factors secreted by these
cells that compromise tissue structure and function. Once a cell
has entered senescence, its transcriptome is altered such that genes
associated with angiogenesis are activated. Inflammatory cytokines
(IL-8), growth factors (TGF-b, EGF), matrix metalloproteinases
(MMPs), and extracellular matrix proteins (laminins, collagens,
fibronectin) are among the genes upregulated by senescent cells
(Zhang et al, 2003; Campisi, 2005; Bavik et al, 2006). This
alteration in expressed genes affects not only the senescent cell
itself, but the cells surrounding it as well. Senescent fibroblasts that
were co-cultured with breast or prostate epithelial cells increased
the proliferation and tumorigenicity of those epithelial cells, both
in vitro and in vivo (Campisi, 2005; Bavik et al, 2006). Senescence,
then, inhibits cancer formation early on but over time the build
up of senescent cells alters the microenvironment to one that can
promote the initiation of epithelial cancers.
Received 12 July 2007; revised 18 October 2007; accepted 19
November 2007; published online 8 January 2008
*Correspondence: Dr MJ Reed; E-mail: mjr@u.washington.edu
British Journal of Cancer (2008) 98, 250–255
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.comClinical observations suggest that while ageing confers the
greatest risk of developing cancer, once initiated, histologically
similar tumours behave less aggressively in the aged individual
(Ershler, 1986). This premise was further supported by animal
studies in which young and aged mice received identical inocula of
tumour cells and were subsequently monitored for tumour growth
and aggressiveness (Kreisle et al, 1990; Pili et al, 1994). Proposed
mechanisms for differences in tumour behaviour in young vs aged
hosts have focused on age-related deficits in immune-mediated
responses that directly and indirectly promote tumour growth
(such as a lack of inflammatory cells and their associated
cytokines), increases in apoptosis, and decreases in pathological
angiogenesis (Ershler, 1986; Kreisle et al, 1990; Pili et al, 1994). The
aged microenvironment, it has been argued, is less permissive to
pathological angiogenesis and tumour growth than the milieu of
tissues found in the young. Such an alteration in tissue architecture
has been thought to be an adaptive response to the greater risk of
cancer conferred by senescence and environmentally induced
changes in the epithelial and stromal cells (Campisi, 2005). More
recently, however, we have shown that prostate epithelial tumours
can provide a microenvironment that allows certain tumours to
grow equally well in aged and young mice (Reed et al, 2007).
The aged microenvironment, likewise, affects the metastasis of
the primary tumour. Recent data from Kaplan et al (2006) suggest
that tumour metastases are determined by preparation of a bone
marrow-derived ‘metastatic niche’ prior to the arrival of cancer
cells (Kaplan et al, 2006). When aged marrow was used to replace
the marrow in young irradiated mice, tumour metastases
decreased. Conversely, when marrow from young donors was
used to replace marrow in older irradiated mice, metastases
increased. Langley and Fidler (2007) further reviewed the myriad
of factors involved in metastases, including the angiogenic
component, and concluded that interactions of the tumour cells
with the host homoeostatic mechanisms are highly variable and
complex (Langley and Fidler, 2007). Therefore, the reasons behind
an apparent decrease in metastases in the aged host vs young host
are many fold and likely vary with the type of cancer. In this
minireview, we will focus on how age-induced modifications of the
microenvironment influence angiogenesis of the primary tumours.
EXTRACELLULAR MATRIX
The specific effects of age on the extracellular matrix have not been
well delineated within the tumour microenvironment. However,
studies of age-related alterations of the matrix in other tissues, and
of changes in tumour matrix in non-aged hosts, provide a basis
for discussion of collagen and laminin, the best studied of these
proteins.
Collagen I is a heterotrimeric, fibrillar protein that is the major
structural extracellular protein in most tissues (Chung et al, 2005).
Collagen I has been the most extensively examined collagen in
aged hosts and the consensus is that ageing confers a progressive
decrease in collagen I synthesis at the same time there is an
increase in collagen I degradation. There are important exceptions
to this premise, such as the increased collagen I deposition that is
often noted in aged hearts (Gazoti Debessa et al, 2001). Although
the cardiac changes are primarily a response to injury or
hypertension, and not ageing per se, the observations with respect
to collagen I underscore the need to use the term ‘deregulation’ to
describe many of the changes in the matrix in aged organs.
Studies examining mechanisms of decreased collagen I content
in aged tissues have noted that lower levels of fibrogenic growth
factors, such as transforming growth factor-b (Ashcroft et al,
1997), contribute to less collagen I synthesis and subsequent
scarring. At the same time, elevated matrix metalloproteinase
activity mediates increased collagen I degradation. Whether the
latter results from an increase in collagenase and other MMPs or a
decrease in tissue inhibitors of MMPs is still a matter of debate,
but the end result is a looser, less organized collagen network
(Hornebeck et al, 2002). Whereas some have suggested that a less
dense collagen matrix facilitates vascular in-growth (Reed et al,
2005), studies of angiogenesis in most organs have demonstrated
decreased capillary density with age (Rivard et al, 1999).
Alterations in collagen I that have functional consequences include
age-related deficits in integrin-collagen binding that result in less
robust cell adhesion and migration (Reed et al, 2001), which could
contribute to delayed tissue repair.
Although diminished collagen I content results in less scarring
and fibrosis in most aged tissues (with the exception of the heart
as noted above), the implications for tumour angiogenesis and
growth are largely a matter of conjecture and depend on the
tumour cell type. For example, we found that the amount of
collagen I in melanomas from aged mice was decreased compared
to levels found in prostate tumours from aged mice; likewise, we
found decreased vessel density in these melanomas compared
to the prostate tumours (Reed et al, 2007). The therapeutic
implications are especially of interest in the treatment of cancers
that produce large quantities of collagen such as prostate. One
could surmise that if a cancer cell can be modified to secrete less
collagen, there will be decreased support for vascular in-growth
and subsequent tumour progression.
While collagen I is the best-studied extracellular matrix protein
in non-tumour aged tissues, the examination of laminins in
tumour angiogenesis has been restricted to non-aged hosts.
Laminins (LM) are large matrix glycoproteins composed of highly
homologous a, b, and g chains and are the main constituent of
basal membranes (a special matrix that separates different cell



















Figure 1 Effects of the aging microenvironment on angiogenesis of
prostate tumours. The presence of senescent cells increases with age.
These cells alter their expression of ECM proteins, which in turns modifies
the composition of the microenvironment. Although the stromal cell has
not been shown to senesce in the prostate, the cytokines produced by
senescent epithelium influence stromal cell function and secretions. Local
increases in hormones, growth factors (such as IGF-1), and matricellular
proteins such as thrombospondin (TSP1) further alter the microenviron-
ment. The aged prostate microenvironment, therefore, contains many
components that are pro-angiogenic, thus supporting the growth of
transformed epithelial cells and enhancing angiogenesis of the primary
tumour in the aged host.
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the tissue architecture, as well as modulators of cell behaviour
(Patarroyo et al, 2002). The laminin a4 chain is expressed by
most endothelial cells throughout the body and plays an important
role in post-developmental angiogenesis associated with inflam-
mation and tumours (Zhou et al, 2004). LM411 (a4b1g1) (formerly
known as laminin-8) facilitates endothelial proliferation and
protects endothelial cells from apoptosis (DeHahn et al, 2004).
Sprouting and tumour blood vessels express LM411, whereas
normal blood vessel maturation and loss of malignant characteris-
tics are associated with conversion to LM421 (a4b2g1) (formerly
known as laminin-9) (Zhou et al, 2004). LM411 facilitates tumour
progression, but the presence of LM421 may be equally important
in preventing metastases, as lama4
/ mice exhibit uncontrolled
blood vessel proliferation following injury and have increased
tumour growth and metastasis (DeHahn et al, 2004; Zhou et al,
2004).
Senescent stromal cells highly secrete laminins. Accordingly,
laminins have been postulated to influence the cancer phenotype
of breast and prostate epithelium. Recent studies have shown that
senescent prostate epithelial cells found in regions of benign
prostatic hyperplasia as well as senescent prostate fibroblasts have
increased expression of the laminin a4 and b1 chains (Luo et al,
2002; Bavik et al, 2006). Fujita et al (2005) also demonstrated a
switch from LM421 to LM411 expression in breast tumour
vasculature, implying that increased expression of the LM411
chains may be associated with progression of some epithelial
cancers (Fujita et al, 2005). This group recently reported
regression of glioblastoma tumours in mice following administra-
tion of LM411 inhibitors (Fujita et al, 2006). It would be of interest
to examine if a similar outcome occurred in mouse models of
breast or prostate cancer since aberrant expression of LM411 by
senescent and epithelial tumour cells appears to influence the
angiogenic potential of adjacent endothelial cells. Thus, in the
aged host, accumulation of senescent cells may facilitate epithelial
tumour growth, in part, via increased expression of laminins
associated with tumour angiogenesis.
MATRICELLULAR PROTEINS
The term matricellular refers to proteins of the extracellular space
that regulate cell function without providing significant structural
support. Although the size of the family of molecules designated
as ‘matricellular’ continues to grow, only a few member proteins
have been examined in aged hosts. Key molecules investigated in
ageing and in tumour biology include thrombospondin 1 (TSP1)
and secreted protein acidic and rich in cystein (SPARC).
Thrombospondin 1 is a large heterotrimer whose expression
increases in most aged cells and tissues (Naumov et al, 2006). The
negative effects of TSP1 on endothelial cell function have resulted
in great interest in this protein in tumour angiogenesis and
progression. In many cancers, TSP1’s presence is associated with
a non-angiogenic phenotype and tumour regression; the absence
of TSP1 expression is correlated with an angiogenic switch
and metastases (Naumov et al, 2006). Thrombospondin 1 inhibits
angiogenesis by blocking growth factor-mediated angiogenic
functions such as proliferation and migration as well as by
enhancing apoptosis in activated endothelial cells (Colombel et al,
2005).
In the prostate, androgens repress the transcription of TSP1.
However, it is now understood that the clinical implications of
TSP1 expression on tumour vascularity and growth depend on
the duration of exposure. Androgen withdrawal initially leads to
increases in TSP1 and vessel regression; however, with continued
exposure prostate cancer angiogenesis and growth continue
despite persistently high levels of TSP1 (Colombel et al, 2005).
Similar results have been reported in breast cancers: persistently
high levels of TSP1 in the tumour stroma ultimately result in
disease progression, an effect that may result from increased
expression of VEGF (Fontana et al, 2005). These conflicting effects
have dampened enthusiasm for the use of fragments of TSP1 in
clinical intervention studies.
Secreted protein acidic and rich in cystein is a secreted
glycoprotein that is highly expressed in injured and inflamed
tissues. Accordingly, high levels of SPARC are found in many aged
organs and in numerous cancers (Framson and Sage, 2004). Intact
SPARC inhibits the angiogenic response by impairing proper
collagen alignment and blocking pro-angiogenic growth factors
(Kupprion et al, 1998). At the same time it has been reported that
cleaved SPARC might facilitate vessel growth by enhancing
endothelial cell proliferation (Sage et al, 2003). In aged tissues,
the complexities surrounding the role of SPARC in the angiogenic
response are obviated by age-related deficits in the levels of growth
factors and other pro-angiogenic mediators (Reed et al, 2005).
Nevertheless, the relative ease by which in vivo SPARC expression
can be manipulated has resulted in continued enthusiasm
for its therapeutic potential in highly vascularized tumours
(Elola et al, 2007).
ANDROGENS
Although serum androgen levels decrease with age, levels of active
androgen in the prostate, dihydrotestosterone, do not decrease due
to increased activity of the 5a-reductase enzyme, which converts
testosterone (T) to dihydrotestosterone (Bonnet et al, 1993). In
malignant prostate epithelium androgens can stimulate angiogenesis
(Colombel et al, 2005). Following androgen withdrawal in
androgen-dependent tumours, there is a decrease in angiogenesis
associated with tumour regression. However, there is invariably a
return of tumour that is castration resistant. These tumours are
commonly referred to as androgen-independent (AI), although
castration-resistant may be a more appropriate term since they still
contain significant levels of T and dihydrotestosterone (Mostaghel
et al, 2007). In castration-resistant tumours, there is an increase in
angiogenesis that is associated with an increase in MMP-9 (London
et al, 2003). These studies indicate that tumour angiogenesis in
prostate cancer is associated first with androgens, then with an
increase in matrix remodelling proteases. Further, these data imply
that anti-angiogenic drugs should be of potential therapeutic
benefit. However, no definitive clinical trials have been published,
which may reflect a unique ability of prostate cancer to bypass the
usual age-associated inhibition of angiogenesis.
GROWTH FACTORS
Although many growth factors regulate the angiogenic response in
the tumour microenvironment, we will focus our discussion on
vascular endothelial growth factor (VEGF) and insulin-like growth
factor-1 (IGF-1). These two traditional growth factors directly
facilitate endothelial cell functions that promote blood vessel
formation and have been examined in prostate cancer progression.
Other mediators, such as IL-8 and associated inflammatory
cytokines that modulate endothelial cell behaviour, will not be
discussed due to their intricate relationship with the immune
system of the host during tumour initiation and growth.
It is generally accepted that ageing compromises the ability of
cells to produce angiogenic growth factors, including VEGF
(Rivard et al, 1999). Vascular endothelial growth factor is the
most potent of the numerous mediators that induce endothelial
cell functions and facilitate new vessel formation. The primary
stimulus for VEGF synthesis is hypoxia. However, the response to
low oxygen tension is blunted in aged tissues as a result of defects
in hypoxia-inducible factor 1 (HIF-1), the transcription factor
responsible for VEGF synthesis (Rivard et al, 2000). Although one
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element of protection against tumour vascularisation and sub-
sequent growth in aged hosts, the clinical data supporting this
premise are lacking. In prostate cancer, while VEGF levels are not
predictive of positive biopsy results (Peyromaure et al, 2005)
higher plasma levels of VEGF are associated with metastases and a
poorer prognosis (Duque et al, 1999). Using a transgenic mouse
model of prostate cancer, Isayeva et al (2007) demonstrated that
inhibitors of the VEGF2 receptor delayed tumour progression only
when administered in the early stages of prostate cancer, before a
significant rise in VEGF levels was observed. This same inhibitor
was ineffective if administered during the later stages of prostate
cancer, when VEGF levels were high (Isayeva et al, 2007). Thus,
the minimal effects on tumour progression in clinical trials
of angiogenesis inhibitors may be due to the advanced stage
of prostate cancer being targeted. It is, therefore, likely that the
decrease in VEGF seen in many tissues with ageing does not inhibit
the development of prostate cancers in aged men. Administration
of angiogenesis inhibitors may be more effective if given earlier in
the course of prostate cancer progression, prior to a rise in VEGF
levels, or in conjunction with other therapeutic interventions such
as androgen ablation.
Insulin-like growth factor-1 is a potent stimulator of cellular
proliferation and survival as well as tumour growth. While serum
levels of IGF decrease with age, within the aged population those
individuals with the highest levels of serum IGF-1 have the greatest
risk of developing epithelial cancers such as prostate cancer (Kaplan
et al, 1999). During progression of prostate cancer, local levels of
both IGF-1 and its receptor (IGF-1R) increase (Kaplan et al, 1999).
Like many growth factors, IGF-1 has the potential to reverse the
age-associated decline in endothelial cell function (Thum et al,
2007). Moreover, IGF-1 upregulates the expression of modulators of
endothelial cell function such as VEGF, MT1-MMP, and MMP2; this
regulation requires signalling through the IGF-1 receptor via both
the PI3 kinase and MAP kinase pathways (Miele et al, 2000; Grzmil
et al, 2004; Zhang et al, 2004). Goel et al (2004) reported that
interactions between the IGF-1R and b1 integrins also activated
signalling through both the PI3 kinase and MAP kinase pathways,
which resulted in enhanced prostate tumour cell migration on and
invasion through the extracellular matrix (Goel et al,2 0 0 4 ) .
Although tumour angiogenesis has been associated with increased
expression of b1 integrins and increased signalling through the PI3K
pathway (Stupack and Cheresh, 2002), the direct effect of IGF-1R-
integrin b1 interactions on vessel growth in cancers has not been
studied. Accordingly it is implied, but not proven, that increased
levels of IGF-1 in the aged prostate could promote endothelial cell
function thereby resulting in similar levels of vascularisation, and
primary tumour growth, in young and old hosts.
MATRIX METALLOPROTEINASES
The extracellular environment contains numerous classes of
enzymes that regulate the controlled degradation of matrix proteins.
Many of these proteases also modulate other cellular functions,
either directly by interacting with receptors at the cell surface or
indirectly by activation of latent molecules in the extracellular
milieu. Within the context of tumour progression and angiogenesis,
the matrix metalloproteinases (MMPs) are the most widely studied
class of molecules. Although it is a widely held belief that tissue
levels of MMPs increase with ageing, more recent studies indicate
that changes in MMP activity in most aged organs reflect a
deregulation rather than pervasive increases (Reed et al, 2000).
Accordingly, some aged tissues show decreased matrix turnover at
the same time others demonstrate increased MMP activity.
During cancer progression, organ and tumour cell-specific
changes in MMPs, rather than host age, determine the influence of
matrix degradative enzymes on subsequent tumour growth. The
lack of a specific and pervasive age effect on MMP levels is
important clinically as it is generally accepted that the ability of
solid tumours to express gelatinases is positively correlated with
their invasive potential and subsequent poor clinical outcomes
(Mancini and Di Battista, 2006). Prostate tumours, in particular,
express increasing amounts of MMP2 and MMP9 as they progress
to higher-grade tumours and greater degrees of metastatic
potential (Wood et al, 1997). The influence of MMPs on tumour
propagation results from both direct and indirect mechanisms
(Mancini and Di Battista, 2006). Direct effects, via degradation of
the matrix, result in a more permissive environment for cell
migration and invasion. The subsequent facilitation of the
angiogenic response results in a greater blood supply to the tumour.
Indirect effects of MMP activity include activation of other pro-MMPs,
cleavage of regulatory precursor molecules at the cell surface,
and induction of nascent chemokines and growth factors that
require enzymatic activation.
We have shown in aged animals that angiogenesis and tumour
growth are inhibited in some solid tumours, such as melanomas,
but in prostate cancer equivalent angiogenesis and tumour growth
occurred in both young and old animals. Moreover, the prostate
tumours had high levels of gelatinase (MMP2 and MMP9)
expression and activity (Reed et al, 2007). The relationship
between a well-formed matrix and MMP expression is expected
as extracellular matrix proteins regulate, in part, the production of
the enzymes responsible for their turnover and degradation
(Phillips and Bonassar, 2005). Once tumour cells express MMPs,
they can induce MMP secretion from their associated stromal cells
thereby further amplifying their potency (Stuelten et al, 2005).
MMP activity also has been shown to be a key component of
VEGF-induced angiogenesis in tumours (Bergers et al, 2000),
reflecting another pathway by which MMPs interact with
components of the ECM to facilitate vessel formation and tumour
growth. Although the modulation of MMPs has resulted in
minimal effects in the therapeutic arena, it is notable that these
studies employed general MMP inhibitors. The development of
more specific and potent MMP inhibitors, in conjunction with
other interventions, may result in improved clinical efficacy.
CONCLUSION
Location, location, location: body-wide levels of factors associated
with angiogenesis may decrease with ageing, but their level of
expression can increase locally. The prostate provides a unique
model for this paradigm. For example, while serum levels of IGF-1
decrease with age, prostatic levels increase during prostate cancer
progression. This local increase in IGF-1 leads to an upregulation
in factors, such as VEGF, MT1-MMP, and MMP2, which modulate
endothelial cell function and subsequent angiogenesis. Further-
more, senescent cells are more prevalent with host age and display
a transcriptome that parallels angiogenesis. Growth factors,
cytokines, MMPs, collagens, laminins, and integrins are all
upregulated by senescent cells. Senescent fibroblasts and epithelial
cells may subsequently alter the local microenvironment to one that
promotes angiogenesis and epithelial tumour growth. Consequently,
while angiogenesis is generally impaired in aged tissues, the local
microenvironment of primary epithelial tumours in the aged host
may be as supportive of angiogenesis as that found in the young.
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